The Pegfilgrastim Biosimilars Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Pegfilgrastim Biosimilars Market?
The market size of pegfilgrastim biosimilars has experienced significant growth recently. The market size was $1.56 billion in 2024 and is projected to reach $1.8 billion in 2025 with a compound annual growth rate (CAGR) of 15.3%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Pegfilgrastim Biosimilars Industry?
The market size for pegfilgrastim biosimilars is projected to reach $3.44 billion in 2029 with a compound annual growth rate (CAGR) of 17.5%.
Download Your Free Sample of the 2025 Pegfilgrastim Biosimilars Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Pegfilgrastim Biosimilars Market?
The key drivers in the pegfilgrastim biosimilars market are:
• Rising prevalence of cancer globally
• Growth in the aging population
• Increase in the number of approvals for pegfilgrastim biosimilars
• Targets and incentives provided by regulatory bodies for biosimilar development
Global Market Segmentation: Identifying Major Pegfilgrastim Biosimilars Industry Segments
The pegfilgrastim biosimilars market covered in this report is segmented –
1) By Application: Chemotherapy Treatment, Transplantation, Other Applications
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies
Pre-order the 2025 Pegfilgrastim Biosimilars Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Pegfilgrastim Biosimilars Market?
The key trends in the pegfilgrastim biosimilars market are:
• The market is seeing a trend towards taking advantage of relaxed regulations to develop superior biosimilars.
• Intense investment in research and development activities for the creation of unique and effective biologics is becoming increasingly recognized.
• Establishing strategic partnerships with major players for enhanced research and developmental activities in new drug designs is becoming more widespread.
• Increasing attention is being given to the production of biosimilars for neutropenia treatment to enhance revenues and product offerings.
Who Are the Top Competitors & Leading Players in the Pegfilgrastim Biosimilars Market?
Major companies in the pegfilgrastim biosimilars market are:
• Amgen
• Mylan N.V.
• Sandoz (a Novartis division)
• Teva Pharmaceutical Industries Ltd.
• Biocon
• Pfizer
• Celltrion Healthcare
• Coherus BioSciences
• Gedeon Richter
• Fresenius Kabi
• Hetero Labs
• Intas Pharmaceuticals
• LG Chem
• Merck KGaA
• Zydus Cadila
• Aurobindo Pharma
• Apotex Inc.
• Dr. Reddy's Laboratories
• Stada Arzneimittel AG
• Reddy's Laboratories
• Shanghai Henlius Biotech
• Alvotech
• EirGenix
• Bharat Biotech
• Kye Pharmaceuticals
• CinnaGen
• Boryung Pharmaceutical
• Sinopharm
Regional Dominance: Which Area Leads the Global Template Market?
North America was the largest region in the pegfilgrastim biosimilars market in 2024
